1H-Indazole-3-carboxamide GSK-3β Inhibitors Selective Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a strong need for selective inhibitors of glycogen synthase kinase 3 beta (GSK-3β) to treat various disorders related to its uncontrolled activation or over-expression, including insulin-resistance disorders, neurodegenerative diseases, mood disorders, cancerous disorders, inflammation, substance abuse disorders, and epilepsies, as existing treatments are inadequate.
Innovation Solution
The use of 1H-indazole-3-carboxamide compounds, which have a high affinity for GSK-3β, selectively inhibiting its activity to treat conditions arising from uncontrolled activation or over-expression of GSK-3β, including type-2 diabetes, Parkinson's disease, bipolar disorders, prostate cancer, and epilepsy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for GSK-3β-related disorders, then treatment coverage is provided, but treatment effectiveness is inadequate due to lack of selective inhibition
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure parameters of the compounds to achieve high selectivity for GSK-3β. The specific structural parameters (substituents at positions 1, 3, and 5 of the indazole core) are optimized to match the binding pocket characteristics of GSK-3β, resulting in compounds that selectively inhibit this kinase while sparing other kinases.
Solution Approach 2:
The patent employs local quality by introducing specific substituent groups at defined positions on the indazole core. These local structural modifications (such as fluorine atoms, methyl groups, or aromatic substituents) create localized interactions with specific amino acid residues in the GSK-3β binding site, enhancing selectivity without affecting the overall compound framework.
2Measurement precision
If selective GSK-3β inhibitors are developed, then treatment specificity is improved, but compound complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the inhibitor molecule into distinct functional segments: a core indazole-3-carboxamide structure that provides baseline GSK-3β binding, and separate substituent groups at positions 1, 3, and 5 that provide selective interactions. This modular approach allows systematic optimization of selectivity while maintaining structural manageability.
Data Source
AI summary
The present invention relates to the new use of 1H-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta (GSK-3β) inhibitors and to their use in the treatment of GSK-3β-related disorders such as, for example, (i) insulin-resistance disorders; (ii) neurodegenerative diseases; (iii) mood disorders; (iv) schizophrenic disorders; (v) cancerous disorders; (vi) inflammation, (vii) substance abuse disorders; and (viii) epilepsies.